Comorbidity and competing risks for mortality in men with prostate cancer

Accurate estimation of life expectancy is essential for men deciding between aggressive and conservative treatment of prostate cancer. The authors sought to assess the competing risks of nonprostate cancer and prostate cancer mortality among men with differing Charlson comorbidity index scores and tumor risks.

[1]  M. Resnick,et al.  Survival of patients with hormone refractory prostate cancer in the prostate specific antigen era. , 2004, The Journal of urology.

[2]  A. D'Amico,et al.  Guideline for the management of clinically localized prostate cancer: 2007 update. , 2007, The Journal of urology.

[3]  D. Lubeck,et al.  Assessment of prognosis with the total illness burden index for prostate cancer , 2007, Cancer.

[4]  F. Saad,et al.  A nomogram predicting 10-year life expectancy in candidates for radical prostatectomy or radiotherapy for prostate cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  P. Walsh,et al.  Radical prostatectomy versus watchful waiting in early prostate cancer. , 2005, The Journal of urology.

[6]  L. Bouter,et al.  How to measure comorbidity. a critical review of available methods. , 2003, Journal of clinical epidemiology.

[7]  Ronald C. Chen,et al.  Time course and predictors of symptoms after primary prostate cancer therapy. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  D. Fryback,et al.  Long-term survival among men with conservatively treated localized prostate cancer. , 1995, JAMA.

[9]  M. Menon,et al.  Long-term survival probability in men with clinically localized prostate cancer: a case-control, propensity modeling study stratified by race, age, treatment and comorbidities. , 2004, The Journal of urology.

[10]  R A Stephenson,et al.  Urinary and sexual function after radical prostatectomy for clinically localized prostate cancer: the Prostate Cancer Outcomes Study. , 2000, JAMA.

[11]  F. Saad,et al.  Accuracy of life tables in predicting overall survival in patients after radical prostatectomy , 2008, BJU international.

[12]  J. Fowler,et al.  Co-morbidities and survival of men with localized prostate cancer treated with surgery or radiation therapy. , 1996, The Journal of urology.

[13]  A. D'Amico,et al.  NCCN clinical practice guidelines in oncology: prostate cancer. , 2010, Journal of the National Comprehensive Cancer Network : JNCCN.

[14]  Dirk F Moore,et al.  Outcomes of localized prostate cancer following conservative management. , 2009, JAMA.

[15]  D. Fryback,et al.  The impact of co-morbidity on life expectancy among men with localized prostate cancer. , 1996, The Journal of urology.

[16]  Anthony D'Amico,et al.  Prostate cancer. Clinical practice guidelines in oncology. , 2007, Journal of the National Comprehensive Cancer Network : JNCCN.

[17]  Mark S Litwin,et al.  Survivorship beyond convalescence: 48-month quality-of-life outcomes after treatment for localized prostate cancer. , 2009, Journal of the National Cancer Institute.

[18]  Kevin Regan,et al.  Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  J. Satagopan,et al.  A note on competing risks in survival data analysis , 2004, British Journal of Cancer.

[20]  S. Boorjian,et al.  Mayo Clinic validation of the D'amico risk group classification for predicting survival following radical prostatectomy. , 2008, The Journal of urology.

[21]  John T. Wei,et al.  Comprehensive comparison of health-related quality of life after contemporary therapies for localized prostate cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  E. Bergstralh,et al.  Long-term hazard of progression after radical prostatectomy for clinically localized prostate cancer: continued risk of biochemical failure after 5 years. , 2000, The Journal of urology.

[23]  Alan W Partin,et al.  Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. , 2005, JAMA.

[24]  Robert Gray,et al.  A Proportional Hazards Model for the Subdistribution of a Competing Risk , 1999 .

[25]  C. Mackenzie,et al.  A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. , 1987, Journal of chronic diseases.

[26]  Haesook T. Kim.  Cumulative Incidence in Competing Risks Data and Competing Risks Regression Analysis , 2007, Clinical Cancer Research.

[27]  M. Cowen,et al.  Predicting life expectancy in men with clinically localized prostate cancer. , 2006, The Journal of urology.

[28]  S B Malkowicz,et al.  Biochemical Outcome After Radical Prostatectomy , External Beam Radiation Therapy , or Interstitial Radiation Therapy for Clinically Localized Prostate Cancer , 2000 .

[29]  Hans Garmo,et al.  Radical Prostatectomy versus Watchful Waiting in Early Prostate Cancer , 2011 .

[30]  J. Hanley,et al.  Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer. , 1999, JAMA.